Ong Darren Suryawijaya, Harris Matthew, Hart John D, Russell Fiona M
Asia-Pacific Health, Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia.
Vaccines (Basel). 2025 May 9;13(5):503. doi: 10.3390/vaccines13050503.
Rotavirus is a major cause of acute gastroenteritis (AGE) in children <5 years. While rotavirus vaccines are effective in reducing AGE, limited data on their indirect effects exist. The aim of our narrative systematic review was to summarise the indirect effects of rotavirus vaccines on unvaccinated children and adults (PROSPERO: CRD42023418015). Peer-reviewed articles and conference abstracts were searched through Medline, Embase and PubMed on 8 December 2024. Observational studies of national/regional vaccine introduction were included. We included five outcomes: rotavirus-AGE inpatient admissions, rotavirus-AGE outpatient attendances, all-cause AGE inpatient admissions, all-cause AGE outpatient attendances, and stool rotavirus positivity. Outcome measures reported as percent reduction or individual incidence rates for the pre- and post-introduction periods were transformed to incidence rate ratios (IRRs). Median IRRs and interquartile ranges (IQRs) were calculated for each outcome by age group (<5, 5-19, and >18 years). From an initial 757 articles, 44 studies including 9,327,974 participants were included. In unvaccinated children <5 years, there were reductions in rotavirus-AGE admissions (median IRR: 0.62, IQR: 0.40-0.82), rotavirus-AGE outpatient attendances (0.74, 0.16-0.98), all-cause AGE admissions (0.70, 0.56-0.86), and stool rotavirus positivity (0.42, 0.31-0.57), but not all-cause AGE outpatient attendances (0.92, 0.78-1.17). Few studies reported these outcomes for children and adolescents aged 5-19 years and adults >18 years. Indirect effects appeared to be greater in higher income and lower under-five mortality settings. Understanding these indirect benefits is crucial for evaluating the broader impact and cost-effectiveness of rotavirus immunisation programs.
轮状病毒是5岁以下儿童急性胃肠炎(AGE)的主要病因。虽然轮状病毒疫苗在降低AGE方面有效,但关于其间接影响的数据有限。我们叙述性系统评价的目的是总结轮状病毒疫苗对未接种疫苗的儿童和成人的间接影响(国际前瞻性系统评价注册库:CRD42023418015)。2024年12月8日通过Medline、Embase和PubMed检索了同行评审的文章和会议摘要。纳入了关于国家/地区引入疫苗的观察性研究。我们纳入了五个结局:轮状病毒AGE住院入院、轮状病毒AGE门诊就诊、全因AGE住院入院、全因AGE门诊就诊和粪便轮状病毒阳性。将引入疫苗前后时期报告为降低百分比或个体发病率的结局指标转换为发病率比(IRR)。按年龄组(<5岁、5 - 19岁和>18岁)计算每个结局的中位数IRR和四分位间距(IQR)。从最初的757篇文章中,纳入了44项研究,包括9327974名参与者。在5岁以下未接种疫苗的儿童中,轮状病毒AGE住院入院(中位数IRR:0.62,IQR:0.40 - 0.82)、轮状病毒AGE门诊就诊(0.74,0.16 - 0.98)、全因AGE住院入院(0.70,0.56 - 0.86)和粪便轮状病毒阳性(0.42,0.31 - 0.57)有所降低,但全因AGE门诊就诊未降低(0.92,0.78 - 1.17)。很少有研究报告5 - 19岁儿童和青少年以及18岁以上成年人的这些结局。在高收入和五岁以下儿童死亡率较低的环境中,间接影响似乎更大。了解这些间接益处对于评估轮状病毒免疫计划的更广泛影响和成本效益至关重要。